Interviews

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Guillermo Garcia-Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic syndrome.

A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment choices.

Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.

With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.

Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which involves tailored strategies including rinses, eye drops, and close monitoring.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal cancer.

Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.

John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments for diseases like colon cancer.

Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab and balstilimab in colorectal cancer.

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, highlighting urgent needs for systemic change.

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for various cancers.

A recent study highlights disparities in federal cancer funding, revealing that high-mortality cancers like lung and liver are significantly underfunded.

Benjamin Schlechter, MD, discusses the unmet needs and treatment gaps for patients with colorectal cancer.

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a reevaluation of routine imaging practices.